Menarini Group's Elacestrant Granted Priority Review by the U....
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
FLORENCE, Italy and NEW YORK, August 11, 2022 /PRNewswire-AsiaNet/ -- Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancerSubmission supported by results from the pivotal ...
Authors: LATEST ASIANET NEWS RELEASES
